Quick answer

A case report documents an observed event in one person or a small number of people. A safety signal is information suggesting a possible new association or a new aspect of a known risk that deserves investigation. A confirmed risk requires a stronger body of evidence that evaluates timing, alternative explanations, comparison rates, biological plausibility, consistency, and the quality of the underlying data.

What a case report can tell us

Case reports can provide early warnings, especially for unusual or serious events that may not appear in a clinical trial. They can describe timing, clinical features, laboratory findings, other exposures, and what happened after an exposure stopped or resumed.

A case report usually cannot determine how often an event occurs or prove that one exposure caused it. There may be no comparison group, and the event could reflect an underlying condition, another product, contamination, interaction, or coincidence. The value is in identifying a question that larger and more structured research can examine.

Spontaneous adverse-event reports

Programs such as FDA MedWatch collect reports from health professionals, patients, and consumers. These systems can detect unusual patterns across many products and settings. They are particularly useful after a product reaches a larger and more diverse population than a trial could include.

Reports do not establish causation on their own. Submission is incomplete and uneven, the number of exposed people may be unknown, duplicate reports can occur, and publicity can change reporting behavior. A high report count cannot be read as an incidence rate without an appropriate denominator and validated case definition.

What makes something a safety signal

A signal can emerge from case reports, surveillance databases, clinical trials, observational studies, laboratory findings, or a combination of sources. It may concern a previously unrecognized event, a more severe outcome, a higher frequency, a susceptible subgroup, or an interaction.

A signal means investigate. It does not mean the association has been confirmed. Investigators may review case details, compare observed and expected patterns, examine timing and dose-response information, search other databases, and conduct targeted studies.

How risks become better established

Stronger evidence often comes from convergence. Controlled trials can compare adverse outcomes between randomized groups, although they may be too small or short for rare and delayed harms. Observational studies can evaluate large populations and longer periods, but confounding and measurement limitations remain.

Active surveillance systems can apply predefined analyses across health records or claims data. Mechanistic evidence may show whether a proposed pathway is plausible. Consistency across independent sources raises confidence, especially when alternative explanations have been addressed.

Frequency and severity are different questions

A rare event can be important if it is severe. A common event can still require careful characterization if it changes adherence, function, or quality of life. Risk communication should describe both the probability and the seriousness of the outcome.

Absolute numbers matter. Relative comparisons without baseline rates can exaggerate or minimize a risk. The relevant population and follow-up period should also be clear.

Evidence level still matters

In vitro findings can suggest toxicity mechanisms but do not establish a human event rate. Animal studies can reveal hazards in a model but may not predict human susceptibility. Human observational data can identify associations, while controlled human evidence generally supports stronger causal conclusions when feasible.

No single hierarchy solves every safety question. Rare harms may never be practical to study in a randomized trial. In those cases, carefully evaluated case series, surveillance data, and multiple observational designs can provide important evidence.

How to read a safety claim

  • Is the source a case report, reporting database, trial, or comparative study?
  • Was exposure verified and was the event clearly defined?
  • Did the event occur in a biologically plausible time window?
  • Were underlying illness, other products, and alternative causes evaluated?
  • Is there a denominator showing how many people were exposed?
  • Are absolute rates and uncertainty reported?
  • Has the pattern appeared in independent data sources?
  • Does the conclusion distinguish a signal from a confirmed causal risk?

Related reading

The bottom line

Case reports and safety signals are essential early-warning tools, but they should not be described as confirmed risks without further evaluation. Credible safety communication states the evidence source, uncertainty, frequency, severity, and alternative explanations. It also updates the conclusion as stronger data become available.